X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
In preclinical studies, SBI100 OE demonstrated superior lowering of intraocular pressure, a key risk factor in disease progression related to glaucoma, in terms of intensity and duration when compared to currently “standard of care” drugs.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Ophthalmology Product Name: SBI-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Skye Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 28, 2022
Details:
R-107 is a liquid, nitric oxide-releasing compound with issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia and South Korea.
Lead Product(s): Nitric oxide-releasing compound
Therapeutic Area: Cardiology/Vascular Diseases Product Name: R-107
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Claritas Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
